6-8
Oct
2026
Barbados Pharmaceutical Inc.
About Barbados Pharmaceutical Inc.
Categories
Meet us at
-
CPHI Milan 2026
Fiera Milano, Italy
6 Oct 2026 - 8 Oct 2026
-
Country/Region:Barbados
-
Founded:2023
-
On CPHI since:2026
-
Employees:1 - 24
Company types
Primary activities
Products from Barbados Pharmaceutical Inc. (14)
-
Product Biologics and Biosimilars Partnership, Barbados
Barbados's national sector strategy places biologics feasibility in Phase 3, 2030 to 2035, alongside API synthesis feasibility and regional R&D anchored at the Barbados Living Laboratory.
A 2030 build needs its partners identified in 2026. BPI is at CPHI Milan to open those conv... -
Product Caribbean Natural Products and Marine Bioactives, Barbados
The Caribbean has an ethnopharmacological tradition and a marine environment that between them represent an underworked source of natural product candidates.
BPI's national sector strategy identifies evidence-based traditional and natural products as a long term opportunity area, coverin... -
Product CARICOM Market Access and Regulatory Pathway
CARICOM is a set of markets with no single registration route. Manufacturers who could serve the region often do not, because the pathway is unclear and no one market justifies the effort on its own.
Barbados is building national regulatory capability, and regional review is available th... -
Product Digital Systems Partnership for a New GMP Facility, Barbados
Most pharmaceutical digital projects are retrofits onto plants that were running before the systems arrived. Barbados is specifying its stack before the facility exists. BPI's national sector strategy sets a digital systems stack of LIMS, ERP and eDMS, compliant with FDA 21 CFR Part 11 and EU Annex... -
Product Pharmaceutical Development Base, Barbados
Place your generic development work in Barbados: stability testing, bioequivalence and reformulation. IP income is taxed at 4.5 per cent, and development spend carries a 50 per cent R&D credit and a 25 per cent productivity and innovation credit.
Barbados sits in ICH Zone IVb. That matters... -
Product Pharmaceutical Manufacturing Investment and Partnership, Barbados
BPI was established by the Government of Barbados to build pharmaceutical manufacturing capability and position the country as a production and distribution point for CARICOM and the Global South.
BPI holds the national pharmaceutical sector strategy. For a manufacturer or investor weigh... -
Product Pharmacovigilance and Post-Market Surveillance, Caribbean
Manufacturers selling into Caribbean markets carry pharmacovigilance and post-market surveillance obligations, with very little capacity in the region to meet them.
Barbados holds genomic sequencing and molecular diagnostics capacity at the Barbados Living Laboratory, launched at the Best-do... -
Product Regional Bioequivalence Centre for CARICOM, Barbados
Generic manufacturers registering into CARICOM run their bioequivalence studies outside the region or through a small number of bridging facilities elsewhere in the Caribbean. Either route adds cost and schedule to every submission, with in vivo studies running to six figures per product.
... -
Product Regional Distribution and Supply into CARICOM
CARICOM is a set of small markets that most manufacturers treat as not worth serving one country at a time. Aggregated, the demand is real, and the Eastern Caribbean is reached from Barbados.
PAHO operates its regional public health hub for the Eastern Caribbean from Barbados.
... -
Product Route to Market: CARICOM and Regional Public Procurement
CARICOM is fifteen markets and most manufacturers skip it, because no single one justifies a registration on its own.
CARPHA's Caribbean Regulatory System reviews a dossier once for the region, which cuts the work per market without removing the national step. Two buyers carry the volume: the ... -
Product Stability Testing, ICH Zone IVb (30°C / 75% RH), Barbados
Products registered across the Caribbean, Brazil, India and the ASEAN markets require stability data generated at ICH Zone IVb conditions, 30°C ±2°C and 75% relative humidity ±5%. Data from a European laboratory at 25°C and 60% RH will not satisfy those regulators.
Barbados sits in Zone I... -
Product Sterile Manufacturing Partnership, Barbados
BPI's joint venture with AMA delivered its first shipment of intravenous solutions to Barbados in March 2026, imported from Nigeria while local manufacturing is built. This would be the first sterile capability in the country.
BPI holds the national pharmaceutical sector strategy...